×
About 9,301 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  3,927 results

Topical medications for chronic plaque psoriasis: a 3-year longitudinal study in France.
https://doi.org/10.1111/dth.14781
Dermatologic Therapy; Mahe E, Moumane SH et. al.

Jan 17th, 2021 - Topical treatments are first-line therapies, prescribed to most patients with chronic plaque psoriasis. This non-interventional, longitudinal study examined data regarding the treatment pathways of French patients with psoriasis vulgaris using a p...

Risk of respiratory infection in patients with plaque psoriasis.
https://doi.org/10.1016/j.jaad.2020.12.083
Journal of the American Academy of Dermatology; Svedbom A, Mallbris L et. al.

Jan 13th, 2021 - Risk of respiratory infection in patients with plaque psoriasis.|2021|Svedbom A,Mallbris L,Ståhle M,|

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic ther...
https://doi.org/10.1111/jdv.17109
Journal of the European Academy of Dermatology and Venere... Thaçi D, Soliman AM et. al.

Jan 11th, 2021 - In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab had greater and more rapid disease improvements compared with those who received fumaric acid ester...

Long-Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazar...
https://doi.org/10.1111/jdv.17113
Journal of the European Academy of Dermatology and Venere... Lebwohl MG, Stein Gold L et. al.

Jan 11th, 2021 - The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a fixed-combination HP 0.01%/TAZ 0.045% lotion has be...

Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis.
https://www.ncbi.nlm.nih.gov/pubmed/33423430
Dermatology Online Journal; Ghiam N, Ojong O et. al.

Jan 11th, 2021 - Lichen Planus (LP), the prototype of lichenoid dermatoses, is an idiopathic, T cell-mediated, autoimmune, inflammatory disease. It may affect the skin, hair, nails, and mucous membranes. Many clinical variants of LP have been described, including ...

see more →

Guidelines  31 results

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 6th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394160/
Postepy Dermatol Alergol; Michalska

Jul 13th, 2020 - Psoriasis is an autoimmune, chronic disease determined by environmental and genetic factors. The occurrence of psoriasis is accompanied by metabolic diseases, cardiovascular diseases (CVD) and depression, disturbances on interpersonal interactions...

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
https://www.mdpi.com/1422-0067/21/5/1690/htm
International Journal of Molecular Sciences; Kamata M,et al

Feb 29th, 2020 - Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthriti...

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052356/
Frontiers in Pharmacology; Gisondi P,et al

Feb 24th, 2020 - Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascul...

Comparison of Biologics and Oral Treatments for Plaque Psoriasis
https://jamanetwork.com/journals/jamadermatology/article-abstract/2759772
JAMA Dermatology; Armstrong AW,et al

Feb 4th, 2020 - In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. A meta-analysis o...

see more →

Drugs  209 results see all →

Clinicaltrials.gov  4,457 results

Topical medications for chronic plaque psoriasis: a 3-year longitudinal study in France.
https://doi.org/10.1111/dth.14781
Dermatologic Therapy; Mahe E, Moumane SH et. al.

Jan 17th, 2021 - Topical treatments are first-line therapies, prescribed to most patients with chronic plaque psoriasis. This non-interventional, longitudinal study examined data regarding the treatment pathways of French patients with psoriasis vulgaris using a p...

Risk of respiratory infection in patients with plaque psoriasis.
https://doi.org/10.1016/j.jaad.2020.12.083
Journal of the American Academy of Dermatology; Svedbom A, Mallbris L et. al.

Jan 13th, 2021 - Risk of respiratory infection in patients with plaque psoriasis.|2021|Svedbom A,Mallbris L,Ståhle M,|

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic ther...
https://doi.org/10.1111/jdv.17109
Journal of the European Academy of Dermatology and Venere... Thaçi D, Soliman AM et. al.

Jan 11th, 2021 - In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab had greater and more rapid disease improvements compared with those who received fumaric acid ester...

Long-Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazar...
https://doi.org/10.1111/jdv.17113
Journal of the European Academy of Dermatology and Venere... Lebwohl MG, Stein Gold L et. al.

Jan 11th, 2021 - The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a fixed-combination HP 0.01%/TAZ 0.045% lotion has be...

Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis.
https://www.ncbi.nlm.nih.gov/pubmed/33423430
Dermatology Online Journal; Ghiam N, Ojong O et. al.

Jan 11th, 2021 - Lichen Planus (LP), the prototype of lichenoid dermatoses, is an idiopathic, T cell-mediated, autoimmune, inflammatory disease. It may affect the skin, hair, nails, and mucous membranes. Many clinical variants of LP have been described, including ...

see more →

News  675 results

Topical Tapinarof Effective in Pivotal Psoriasis Trials
https://www.medscape.com/viewarticle/940526

Nov 5th, 2020 - Tapinarof cream 1% applied once daily in patients with plaque psoriasis convincingly hit its primary and secondary endpoints and was well tolerated in two identical pivotal phase 3, randomized trials, Mark G. Lebwohl, MD, reported at the virtual a...

A 38-Year-Old Dog Owner With a Blistering, Itchy Rash
https://reference.medscape.com/viewarticle/939533_3

Oct 28th, 2020 - Discussion Herpes simplex virus infection can affect almost any area of the skin or mucous membranes and presents with localized blistering. Isolation of the virus in tissue culture confirms the diagnosis.[1] In this case, the viral and bacterial ...

Risankizumab Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis
https://www.staging.medscape.com/viewarticle/939593

Oct 22nd, 2020 - NEW YORK (Reuters Health) - Risankizumab treatment significantly improves symptoms, health-related quality of life and mental health among patients with moderate to severe psoriasis, according to findings from two randomized clinical trials. "Thes...

Non-Whites Remain Sorely Underrepresented in Phase 3 Psoriasis Trials
https://www.staging.medscape.com/viewarticle/939516

Oct 20th, 2020 - Non-White patient participation in phase 3 therapeutic trials for plaque psoriasis is less than 15%, according to a recently published analysis of data from the ClinicalTrials.gov database. The exact figure drawn from the survey of 82 trials was 1...

Non-Whites Remain Sorely Underrepresented in Phase 3 Psoriasis Trials
https://www.medscape.com/viewarticle/939516

Oct 20th, 2020 - Non-White patient participation in phase 3 therapeutic trials for plaque psoriasis is less than 15%, according to a recently published analysis of data from the ClinicalTrials.gov database. The exact figure drawn from the survey of 82 trials was 1...

see more →

Patient Education  2 results see all →